Kazuhito Yamamoto
Nagoya, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 86 publications
RB and CHASER as induction therapy for transplant-eligible mantle cell lymphoma.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: June 29, 2025
Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma.
Journal: Japanese journal of clinical oncology
Published: May 07, 2025
Composite mantle cell lymphoma and T-cell prolymphocytic leukemia: a case report.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: April 29, 2025
Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial.
Journal: International journal of clinical oncology
Published: March 13, 2025
JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma 4. Mantle cell lymphoma (MCL).
Journal: International journal of hematology
Published: February 04, 2025
Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study.
Journal: Annals of hematology
Published: October 01, 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Journal: American journal of hematology
Published: January 17, 2024
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Journal: Hematological oncology
Published: December 29, 2023
R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
Journal: British journal of haematology
Published: September 01, 2023
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan.
Journal: Journal of medical economics
Published: September 01, 2023
Last Updated: 09/26/2026